Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.
about
Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.
@en
Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.
@nl
type
label
Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.
@en
Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.
@nl
prefLabel
Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.
@en
Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.
@nl
P2093
P2860
P1476
Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.
@en
P2093
Deepak Yerragolam
Dinara Makenbaeva
Leah Burns
Meg Franklin
Samuel Perez
P2860
P304
P356
10.1080/03007995.2017.1399870
P407
P577
2017-11-02T00:00:00Z